aTyr Pharma, Inc.(US:ATYR) Prnewswire·2025-11-26 13:50Core Viewpoint - aTyr Pharma, Inc. is facing intensified financial and legal pressures following disappointing third-quarter results that missed Wall Street estimates, alongside ongoing securities class action litigation related to misleading information about its drug Efzofitimod [1][5]. Financial Performance - aTyr reported a GAAP EPS loss of -$0.26 for Q3, missing analyst consensus estimates by $0.08 [3]. - The company's revenues were reported at $190,000, indicating a heavy reliance on its clinical pipeline rather than commercial sales [3]. Clinical Developments - Despite the disappointing results from the Phase 3 EFZO-FIT study, aTyr plans to meet with the U.S. FDA in Q1 2026 to discuss the study results and the future of Efzofitimod in treating pulmonary sarcoidosis [4]. - The EFZO-FIT study did not meet its primary endpoint, leading to a significant market reaction with the stock price dropping over 83% in one day, from $6.03 to $1.02 [6]. Legal Issues - The ongoing securities class action litigation alleges that aTyr and its executives provided materially false and misleading information regarding Efzofitimod's efficacy [5]. - The class action period has been expanded to include investors who acquired shares between November 7, 2024, and September 12, 2025, with claims that the company concealed deficiencies in the drug's performance [7]. - Hagens Berman is investigating whether aTyr misled investors about its data and trial design while promoting Efzofitimod's market potential [8].